Skip to main content

HIV-Positive Drinkers Choose Alcohol Over ART


June 11, 2012 (Miami Beach, Florida) — Half of HIV-positive drinkers receiving antiretroviral therapy (ART) intentionally skipped or stopped taking their medications when they consumed alcohol, in the mistaken belief that combining ART drugs and alcohol is somehow toxic, according to a prospective cohort study.
The study, which monitored patients' beliefs about mixing alcohol and ART medicines, was presented here at the 7th International Conference on HIV Treatment and Prevention Adherence.
"It's really a bad idea for people to stop taking their HIV medications, but we found that there was a substantial number of people with HIV who are choosing to stop taking their medication when they are drinking," lead author Seth Kalichman, PhD, from the University of Connecticut, in Storrs, told Medscape Medical News.
"There are many who hold the belief, not only those with HIV infection but those with other chronic diseases, that if they mix their medications with alcohol it creates a toxic poison that is harmful.... However, there is no evidence that mixing alcohol [with antiretroviral medications] increases the harm of the alcohol itself," Dr. Kalichman said.
"Of course, if you have HIV infection and liver disease, that is an entirely different scenario. You should definitely not drink alcohol if you have liver disease," he said.
Study Design and Results
In their study, Dr. Kalichman and his group enrolled 178 people with HIV who consume alcohol and receive ART, and monitored them for 12 months to see how many of them held the false belief and whether those who did were less adherent to their medications than those who did not.
Patients kept an electronic diary on their cell phone, and received daily text messages reminding them to report whether they had consumed alcohol and what and how much they drank.
Adherence to ART was assessed using monthly unannounced pill counts (patients were contacted and asked to count their pills), self-report, and chart abstracted HIV viral load.
The study found that 90 patients (51%) skipped or stopped taking their ART when drinking. The most common reason given for not taking ART when drinking was the belief that to do so would be dangerous.
Patients who believed that this combination was dangerous were 3 times as likely to be treatment nonadherent as those who did not hold the belief; this difference was significant (P < .01).
Those who skipped doses or stopped ART when drinking were also less likely to be virally suppressed, and more likely to have CD4 cell counts below 200 cells/mm3, Dr. Kalichman reported.
The belief about toxic interaction predicted nonadherence to a greater degree than alcohol use itself.
Message to Patients: Don't Skip ART Doses
Dr. Kalichman noted that misinformed beliefs can be easily corrected. "Doctors can tell their patients that it is not a good idea to drink if you are taking medications because you can miss doses, but don't skip your medications just because you are drinking. When it comes to these antiretroviral medications, the harm of missing the medications is greater than the harm of drinking with medications," Dr. Kalichman said.
Medscape Medical News asked Robert Gross, MD, associate professor of medicine, biostatistics and epidemiology at the University of Pennsylvania Perelman School of Medicine in Philadelphia, for his opinion of the study. Dr. Gross's research is in HIV, health promotion, disease prevention, and behavioral change.
"This perception that it is dangerous to take medications and alcohol probably stems from a time in the 1950s and 1960s when combining the 2, particularly barbiturates, would be fatal," said Dr. Gross, who was not part of the study.
"Having heard that you shouldn't take pills and alcohol at the same time, people have perhaps overgeneralized the idea of not taking antiretroviral therapy at a time when they are drinking alcohol," he said.
"Dr. Kalichman suggested that this mistaken belief might be one of the barriers to taking antiretroviral therapy that is most easily dealt with, and I agree with his conclusion," Dr. Gross said.
He added that clinicians could bring up the topic with their patients to make sure they understand that it is best to continue even if they drink.
"Try to probe whether your patients have these misperceptions," Dr. Gross said. "I find one of the things that is challenging for a provider is to conceptualize the way a patient is thinking about their disease or their treatment.... The bottom line is we want to get them to take medications because we know it will lead to treatment success. The goal should be to meet the patient where they are with their beliefs and try to correct the ones that are correctable."
The study was funded by the National Institutes of Health. Dr. Kalichman and Dr. Gross have disclosed no relevant financial relationships.

Comments

Popular posts from this blog

Contact Precautions May Have Unintended Consequences

Contact precautions, including gloves, gowns, and isolated rooms, have helped stem the transmission of hospital pathogens but have also had some negative consequences, according to findings from a new study. Healthcare worker (HCWs) visited patients on contact precautions less frequently than other patients and spent less time with those patients when they did visit, report Daniel J. Morgan, MD, from the University of Maryland School of Medicine and the Veterans Affairs (VA) Maryland Health Care System, Baltimore, and colleagues. Moreover, patients on contact precautions also received fewer outside visitors. "Less contact with HCWs suggests that other unintended consequences of contact precautions still exist," Dr. Morgan and coauthors write. "The resulting decrease in HCW contact may lead to increased adverse events and a lower quality of patient care due to less consistent patient monitoring and poorer adherence to standard adverse event prevention methods (such...

CareFusion Issues Update on Infant Breathing Product Recall

July 5, 2012 — Medical device maker CareFusion has issued an update reminding healthcare providers of its voluntary recall of its Air Life ™ Infant Breathing Circuit, initiated back in May. The US Food and Drug Administration (FDA) has classified this action as a class 1 recall, meaning there is a reasonable probability of serious adverse health consequences or death associated with use of the defective units. The update was posted July 2 on the FDA  Website. On May 29, 2012, CareFusion sent an  Urgent Recall Notice  to customers and distributors stating that the company had identified potential risks associated with the Air Life  Infant Breathing Circuit. The action was initiated after the company received complaints of the Y adapter within the breathing circuit developing cracks during patient use. "If a crack develops in the Y adapter, this could potentially result in a leak in the closed ventilation system, leading to a loss in the intended tidal volum...

FDA Approves Tapentadol ER for Diabetic Neuropathy

August 29, 2012 — The US Food and Drug Administration (FDA) has approved tapentadol extended-release (ER) ( Nucynta , Janssen Pharmaceuticals, Inc) for the management of neuropathic pain associated with diabetic peripheral neuropathy (DPN) in adults for whom a continuous opioid analgesic is required over an extended time. It is the first opioid to receive this indication, the company notes in a statement today. DPN, the most common type of neuropathy, affects an estimated 16% of the more than 25 million Americans who have diabetes. The condition is often unreported and untreated, with an estimated 2 out of 5 cases not receiving care. Tapentadol ER is already approved for the treatment of moderate to severe chronic pain in adults requiring a continuous opioid analgesic for an extended period. It is a centrally acting synthetic analgesic, although the exact mechanism of action is unknown, the release states. "Although the clinical relevance is unclear," the company n...